Encourage Pharmacy Independence, Etana Conducts Clinical Research On Diabetes Therapy With RSUI

JAKARTA - PT Etana Biotechnologies Indonesia (Etana), a national biofarmasi company focused on developing products for metabolic and chronic diseases, signed a cooperation agreement with the University of Indonesia Hospital (RSUI) for the implementation of clinical research on Type 2 diabetes Mellitus therapy.

This step is part of Etana's commitment to providing biotechnology-based innovations that have a real impact on public health as well as supporting the independence of the national pharmaceutical industry. The therapeutic products studied are based on cutting-edge technology and are aimed at responding to the challenges of handling chronic diseases whose prevalence continues to increase in Indonesia.

"We believe that clinical research on GLP-1 products in diabetes and obesity is one of the breakthroughs that can make a big contribution, not only from a clinical perspective, but also in supporting the independence of the national pharmaceutical industry," said Etana Chief Finance Officer, Liauw Tek Kim, in Depok on Monday, July 14.

Furthermore, he also said, the drugs developed in this study were the result of local production by Etana in its manufacturing facilities in Indonesia, and were fully carried out by domestic experts. So far, the therapy available in the market is still dominated by imported products. In terms of effectiveness and efficiency, Etana ensures that the quality of its products is equivalent to imported products. However, the main advantage is that the price is much more affordable.

"Our target is to help the Indonesian people so that this therapy can be accessed by all levels of society," he added.

The study was conducted with RSUI as a strategic partner of academics and health services. Clinical trials will be carried out rigorously and scientifically, involving Prof. Dr. dr. Pradana Soewondo, Sp.PD-KEMD endocrinologist as well as academic from the University of Indonesia as the main researcher. The entire process will refer to scientific principles, clinical trial protocols, as well as medical ethics that apply to ensuring the safety and effectiveness of therapy before being widely used by the public.

The President Director of RSUI, dr. Kusuma Januarto, Sp. OG, Subsp. Obginsos, said that the involvement of RSUI in this clinical trial reflects the role of his institution as an educational hospital that actively supports the development of medical science and technology.

"RSUI through safety-oriented clinical research and patient benefits will be part of an innovation of diabetes therapy that has benefits for the community, especially patients with chronic diseases such as diabetes," he said.

As an educational hospital included in the Brand Finance version of the Global Top 250 Hospitals, RSUI also continues to strengthen the collaboration of strategic research both at the national and international levels. This joint research with Etana is concrete evidence of the synergy between the industrial, academic, and health services world.

This collaboration is expected to be the foundation for the development of innovative therapies that are in accordance with the needs of the Indonesian people, as well as strengthen the direction of national health development based on research and science.